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The association between corticosteroid therapy and subsequent infections was calculated
by pooling data from 71 controlled clinical trials. The overall rate of infectious complica-
tions was 12.7010 in the 2,111 patients randomly allocated to systemic corticosteroids and
8.0070 in the 2,087 controls (relative risk [RR], 1.6; 95% confidence interval reI], 1.3-1.9;
P < .001). The risk of infection was particularly high in patients with neurologic diseases
(RR, 2.8; 95% CI, 1.9-4.3; P< .001) and less pronounced in patients with intestinal (RR,
1.4; 95% CI, 1.1-1.7; P = .02), hepatic (RR, 1.4; 95% CI, 0.9-2.3; P = .25), and renal
(RR> 1; P = .03) diseases. The rate was not increased in patients given a daily dose
of <10 mg or a cumulative dose of <700 mg of prednisone. With increasing doses the
rate of occurrence of infectious complications increased in patients given corticosteroids
as well as in patients given placebo, a finding suggesting that not only the corticosteroid
but also the underlying disease state account for the steroid-associated infectious compli-
cations observed in clinical practice.
Corticosteroids in pharmacologic doses are com-
monly used to inhibit the immunologic network [1,
2]. As a consequence one might expect that the re-
sistance to a wide variety of bacterial, viral, proto-
zoal, and fungal agents is depressed, as was clearly
demonstrated by numerous investigations in animals
[3-5]. The effect of corticosteroids on the rate of in-
fection was shown to depend upon many variables,
including the dosage of the steroid and the resistance
of the animal. These observations in animals were
in accordance with the clinical impression of an in-
creased rate of infections in patients treated with
glucocorticoids.
Toxicologic studies in animals allow in many but
not all instances for the prediction of potential ad-
verse effects of a drug in humans and for the estab-
lishment of the underlying mechanism for such un-
wanted effects. However, such studies cannot provide
a quantitative estimate of the rate of occurrence of
a given adverse effect in humans. This might also
be true for corticosteroids. For instance, a large num-
ber of the investigations dealing with the enhance-
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ment of the susceptibility to infectious agents were
performed in so-called steroid-sensitive species, such
as rodents [3-5], whereas humans belong to the
group of steroid-resistant species [1]. The dosages
of corticosteroids given to animals cannot be com-
pared with those given to patients, because virtually
all animal species investigated metabolize corticoste-
roids much faster and exhibit a different binding to
plasma proteins than do humans [6-8]. Furthermore,
some disease states, such as the nephrotic syndrome,
Crohn's disease, alcoholic cirrhosis, structural bron-
chopulmonary diseases, rheumatic diseases, multiple
sclerosis, cerebrovascular diseases, and cranial trau-
ma, which have been or are being treated with cor-
ticosteroids, are considered to predispose to the de-
velopment of infectious diseases [9-16]. Thus, the
clinical evidence of an increased rate of infectious
complications in patients given corticosteroids has
to be considered with caution, and only the analysis
of controlled trials may allow demonstration of a
causal and quantitative relationship between ther-
apy with corticosteroids and appearance of infec-
tions.
Therefore, we examined the association between
corticosteroid therapy and subsequent infectious dis-
eases by pooling data from controlled clinical trials
in which patients were randomized to treatment with
or without systemic corticosteroids. In order to es-
tablish whether the risk of infectious complications
was dose dependent, we calculated the association
between daily doses or cumulative doses of predni-
sone and the rate of infections.
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Glucocorticosteroids and Infections
Methods
In the present investigation results of previous reports
were combined and analyzed. This technique is desig-
nated meta-analysis [17, 18].
Selection criteria. A review of the English-lan-
guage literature in which patients were assigned to
receive systemic corticosteroids or nonsteroid ther-
apy for at least 3 days was performed. For that pur-
pose a MEDLINE computer search was supple-
mented by consultation with reviews, textbooks, and
eXPerts in the fields of hepatology, gastroenterology,
pneumology, neurology, nephrology, and rheuma-
tology and by review of references in all the trials
found. The trials were analyzed according to a pre-
determined protocol.
Only controlled studies were included; studies in
which adrenocorticotropic hormone was adminis-
tered or in which systemic corticosteroid therapy was
combined with cytostatic or other immunosuppres-
sive agents were excluded. Trials in which patients
were given antibacterial, antiviral, antifungal, or an-
tiprotozoal agents were excluded, except when pro-
phylactic isoniazid only was given. Studies were also
excluded if the number of patients allocated to the
treatment or placebo group was not indicated, if not
enough information was given to estimate the dos-
age and duration of therapy, or if adverse effects were
inadequately discussed (see below).
With regard to crossover studies, only data from
the first arm of the study were included. No attempt
was made to supplement data through personal com-
munication. Eventually, 71 trials were included [19-
90] for the final meta-analysis. A list of 58 relevant
publications excluded from the final analysis can be
obtained from the authors.
Complications. For analysis of nonlethal infec-
tious complications, trials with inadequate discus-
sion of adverse effects (i.e., not mentioned at all, not
clearly enumerated for each treatment group, or too
vaguely described) were excluded. If complications
of therapy were described but an infection was not
specifically mentioned, the paper was included on
the assumption that no infectious complication oc-
curred. For the analysis of lethal infectious compli-
cations, only trials specifying the causes of death
were included. An infection was considered lethal
if it was the main cause and not just a contributing
cause of death. If all patients survived the trial, it
was evident that no lethal infectious complication
occurred.
Dosage and duration of therapy. Duration was
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measured as the number of days; if it varied among
the patients in any study, the median duration was
estimated. Steroid dosage was expressed in predni-
sone-equivalent milligrams [90] and evaluated in two
ways - either as a cumulative dose or as a mean daily
dose (cumulative dose divided by duration). If a trial
included children, only adult dosage was considered
for analysis. Thus, the conclusions derived from the
present meta-analysis are only relevant for adult pa-
tients.
Statistical procedures. Statistical analysis for
comparison of the number of infectious complica-
tions per 100 patients between patients with and
without steroid therapy was performed according to
three different methods: simple "I! analysis of the
pooled data, the Mantel-Haenszel technique of pool-
ing individual "I: values (with each study as a stra-
tum), and the Mantel-Haenszel technique using
Yates's correction for "I: values with small numbers
[91]. If the P values derived by all three methods were
on the same side of .05, only the highest is reported;
if they were on both sides of .05, a range is given.
The 95070 confidence interval (CI) of the relative risk
(RR) was calculated with use of the method de-
scribed by Katz et ale [92].
In the analysis of the effect of steroid therapy ad-
justed for duration, the incidence (rate per 1,000 pa-
tients per 21 days) was calculated. The period of 21
days was chosen because it was the median duration
of therapy in the 71 trials analyzed. The 95070 CI and
the P values were calculated by assuming a Poisson
distribution of new cases, with the mean propor-
tional to the number of patient-days observed [93].
For analysis of pooled trials with ~20 infectious com-
plications, an asymptotic 95070 CI was calculated,
while for analysis of pooled trials with <20 infec-
tious complications the exact 95070 CI was used. In
addition, Wilcoxon's rank sum test was used for com-
parison of subgroups of patients (as indicated in
Results).
The analysis of the trials revealed that patients
with a cumulative dose of <500 mg of prednisone
or a mean dose of <10 mg of prednisone daily had
no more infectious complications than did controls.
For these subgroups of patients, a Type II error anal-
ysis was performed, again assuming a Poisson dis-
tribution [93].
Results
In all, 4,198 patients (1,969 male, 1,415 female, 814
unknown) were analyzed. It was not possible to ana-
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lyze the infectious complications according to age
and/or sex because not enough information was
given in the reports of the trials. In order to estimate
the age of all the patients investigated, the median
value (range) of the median or mean age given in
46 trials was used: 46.1 years (25.8-74.5 years). The
underlying diseases were: pulmonary diseases (364
patients), liver diseases (979), neurologic diseases
(1,223), nephrotic syndrome (197), rheumatic diseases
(167), inflammatory bowel diseases (807), and other
diseases (461).
Among the 71 trials, 23 papers reported infectious
complications. In 16 (70070) of these 23, the steroid
group had more lethal and nonlethal infections than
the controls, while in five trials (22070) the controls
had more infections and in two (9070) an identical
number of infections were reported in both groups.
The overall rate of lethal and nonlethal infectious
complications was 12.7070 in the steroid-treated pa-
tients and 8.00/0 in the controls (P < .(01) (table 1).
Both lethal and nonlethal complications were in-
creased in patients given corticosteroids, the relative
risk being 2.6 (95% CI, 1.2-5.3) and 1.6 (1.3-1.9),
respectively.
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When separate analyses were performed for double-
blind studies, studies using oral steroids, and studies
using parenteral steroids, similar increased relative
risks were found (table 1). When the 10 trials includ-
ing both adults and children were excluded from
analysis, similar statistically significant differences
of infectious complications between the patients with
and without steroids were observed (results not
shown). In three investigations more than one infec-
tion per patient was possible, while in the remaining
68 trials, not more than one infection per patient was
reported. When only these 68 trials were analyzed,
similar differences were found between patients given
steroids and controls (results not shown).
The relative risk in steroid-treated patients with
a mean dose-of <20 mg/d was 1.3 (95070 CI, 1.0-1.6),
as compared with 2.1 (1.3-3.6) in patients treated with
a mean dose of 20-40 mg/d. When patients were
given a mean daily dose >40 mg, no further increase
in the relative risk was observed (table 2). This may
be best explained by the shorter median duration of
therapy in the patients given >40 mg of prednisone/d
than in those given 20-40 mg/d (median 12 days,
range 3-180 days vs. median 28 days, range 6-180
Table 1. Analysis of lethal and nonlethal infectious complications in steroid-treated and control patients.
No. of
infectious
No. of complications/
Category
patients 100 patients
of trial Steroid- Steroid- P Relative risk
Incidencet (95 % CI)
p
(no.) treated Control treated Control value (95% CI) Steroid-treated Control value
Total
All (71) 2,111 2,087 12.7 8.0 <.001 1.6 (1.3-1.9) 11.9 (10.4-13.3) 7.5 (6.4-8.7) <.001
Lethal (71) 2,111 2,087 1.2 0.5 .02 2.6 (1.2-5.3) 1.1 (0.7-1.6) 0.5 (0.2-0.8) .009
Nonlethal (56) 1,665 1,669 14.7 9.4 <.001 1.6 (1.3-1.9) 18.3 (16.0-20.6) 12.1 (10.2-13.9) <.001
Double-blind
All (56) 1,551 1,507 15.7 10.1 <.001 1.5 (1.3-1.9) 26.1 (22.8-29.3) 18.0 (15.2-20.9) <.001
Lethal (56) 1,551 1,507 0.9 0.2 .03 4.5 (1.3-15.8) 1.5 (0.8-2.3) 0.4 (0.1-1.0) .01
Nonlethal (42) 1,405 1,433 16.4 10.5 <.001 1.6 (1.3-1.9) 26.3 (22.9-29.7) 18.9 (15.9-21.9) .001
Oral steroids*
All (52) 1,550 1,574 10.5 7.4 .003 1.4 (1.1-1.9) 7.3 (6.1-8.4) 5.4 (4.4-6.4) .01
Lethal (52) 1,550 1,574 0.6 0.1 .02-.19 5.1 (1.1-23.1) 0.5 (0.2-0.8) 0.1 (0.01-0.3) .02
Nonlethal (40) 1,131 1,184 13.5 9.8 .005 1.4 (1.1-1.9) 11.8 (9.9-13.6) 9.1 (7.5-10.8) .007
Parenteral steroids*
All (13) 459 397 21.8 9.3 <.001 2.3 (1.6-3.3) 484.1 (389.2-579.0) 211.6 (143.4-279.8) <.001
Lethal (13) 459 397 3.1 1.5 .15 2.0 (0.8-5.2) 67.8 (37.0-103.3) 34.3 (12.6-74.3) .14
Nonlethal (12) 432 369 19.9 8.4 .004 2.4 (1.6-3.5) 424.2 (334.6-513.9) 181.4 (117.6-245.3) <.001
* Six trials could not be included in these two (oral or parenteral) categories because combined oral and parenteral therapy was administered
in these trials.
t Number of infectious complications/(1,OOO patients· 21 d).
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Table 2. Lethal and nonlethal infectious complications, according to mean daily steroid dose, median duration of therapy,
and total cumulative steroid dose.
Infectious
No. of complicationsl
Category
patients 100 patients
of trial Steroid- Steroid- P Relative risk
Incidence* (95 % CI)
p
(no.) treated Control treated Control value (95% CI) Steroid-treated Control value
Daily steroid dose
(mg)
<20 (13) 657 689 17.8 14.2 .03-.07 1.3 (1.0-1.6) 5.8 (4.8-6.9) 5.0 (4.0-6.0) .27
20-40 (31) 652 621 6.8 3.2 .003 2.1 (1.3-3.6) 22.6 (16.0-29.2) 10.6 (6.0-15.3) .004
>40 (27) 802 777 13.5 6.3 .005 2.1 (1.6-2.9) 150.7 (122.3-179.2) 66.5 (47.9-85.1) <.001
Duration of
therapy (d)
<30 (43) 1,062 998 10.5 4.7 .001 2.3 (1.7-3.4) 177.0 (144.4-209.6) 81.9 (58.5-105.3) <.001
~30 (28) 1,049 1,089 15.0 11.0 .007 1.4 (1.1-2.3) 7.1 (6.0-8.2) 5.6 (4.6-6.5) .04
Cumulative steroid
dose (mg)
<500 (15) 264 247 0.8 0.8 .95 0.9 (0.1-6.6) 12.2 (1.5-44.0) 13.0 (1.6-46.7) .95
500-999 (19) 422 432 5.3 2.7 .05-.27 2.0 (1.0-3.9) 49.1 (29.0-69.2) 25.3 (11.6-39.7) .06
1,000-1,999 (13) 306 266 14.7 5.6 .02 2.6 (1.5-4.6) 83.9 (59.4-108.4) 29.2 (16.4-44.0) <.001
~2,OOO (24) 1,119 1,142 17.9 12.1 <.001 1.5 (1.2-1.8) 9.3 (8.0-10.5) 6.6 (5.5-7.7) .002
* Number of infectious complications/(l,ooo patients· 21 d).
days; P < .01, Wilcoxon's rank sum test). Similarly
the lower relative risk in patients treated for ~30 days,
compared with that in patients treated for <30 days
(table 2), can be explained by the lower mean daily
dose in the patients treated for ~30 days (median
26.7 mg, range 5-50 mg vs. median 41 mg, range
5-1,926 mg; P < .001, Wilcoxon's rank sum test).
One might anticipate that both the daily dose of
prednisone and the duration of therapy determine
the incidence of infectious complications. The com-
bined impact of these two determinants on the inci-
dence of infectious complications is illustrated in fig-
ure 1. From that figure it can be seen that in none
of the 21 trials with a cumulative dose of <700 mg
of prednisone was the number of infectious compli-
cations reported in steroid-treated patients higher
than in controls. A Type II error analysis revealed
that an increase in the frequency of infectious com-
plications from 0.8070 (table 2) to >2.4070 in the pa-
tients on a cumulative corticosteroid dose of <500
mg can be rejected at the 0.05 confidence level. In
none of the five trials with a mean daily dose of <10
mg of prednisone were more infectious complications
reported in the patients given steroids than in the con-
trols (figure I). An incidence of >1.1 infectious com-
plications/[I,OOO patients·21 d], or >3.3 infectious
complications/IOO patients, can be rejected for the
patients given <10 mg prednisone/d at the 0.05 con-
fidence level.
The incidence of infectious complications in pa-
tients with different underlying diseases is shown in
table 3. In patients with pulmonary and rheumatic
diseases, no infections were observed in steroid-
treated and in control patients. In the other five dis-
ease states, the frequency of infectious complications
in steroid-treated patients ranged from 1.8 to 33.9/
100 patients and from 0.0 to 24.9/100 patients in the
control subjects (frequencies for the individual cat-
egories of trials are not shown in table 3). The result-
ing relative risk was >1 in each of these five strata,
being highest in patients with neurologic diseases
(RR, 2.8; 950/0 CI, 1.9-4.3; P < .001), and less pro-
nounced in patients with intestinal (RR, 1.4; 95%
CI, 1.1-1.7; P = .02), hepatic (RR, 1.4; 95% CI,
0.9-2.3; P = .25), renal (RR, >1; 95070 CI not quan-
tifiable because of zero in the denominator; P = .03),
and other diseases (RR, 1.1; 95% CI, 0.3-4.3; P =
.95) (RR derived from frequencies not shown in ta-
ble 3).
Discussion
The main purpose of a controlled clinical trial of
corticosteroids is to establish the efficacy of such
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Figure 1. Double-logarithmic plot of
the mean daily dose of prednisone vs.
the median duration of therapy in 71
controlled trials. Each symbol repre-
sents one trial. The position of a sym-
bol reflects the mean daily dose of
prednisone (y axis) and the median du-
ration of therapy prescribed (x axis) in
a given trial. The closed squares (_)
represent trials with a higher numeri-
cal incidence of infectious complica-
tions in the group of patients treated
with prednisone than in the group of
controls, -whereas the open circles (0)
represent trials without a higher inci-
dence of infectious complications in
patients given prednisone than in con-
trols. The product of the duration of
therapy times the daily dose is the cu-
mulative dose of prednisone prescribed.
The cumulative dose of 700 mg of pred-
nisone is given by the oblique line. Note
that all trials with a higher incidence
of infections in patients given predni-
sone than in those given placebo are lo-
cated above the isodose line of 700 mg,
an indication that, independent of the
dosage regimen, patients with a cumula-
tive dose of <700 mg had no increased
risk of infectious complications.
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therapy in a disease state. Special emphasis is there-
fore given to the assessment of the final therapeutic
objective while the assessment of the adverse effects
may be neglected. Thus, the report of the multiple
adverse effects is usually much less detailed than the
report of the impact of the corticosteroid on the un-
derlying disease state. As a consequence, publica-
tions dealing with corticosteroid therapy might be
qualitatively or quantitatively deficient with regard
to the report of infectious complications. The qual-
itative deficiency in reporting infectious complica-
tions is clearly demonstrated by the fact that in <8070
of the infections reported was the nature of the in-
fectious disease, i.e., bacterial, viral, fungal, or pro-
tozoal, indicated.
On the basis of the data given in the publications
of the controlled trials, it cannot be established
whether all or only a fraction of the infectious com-
Table 3. Number of patients, daily prednisone dose, and duration of therapy in steroid-treated and control patients, according
to the underlying disease state.
No. of patients Median daily Median duration
steroid dose of therapy Incidence* (95 % CI)
Category of Steroid- in mg in days P
trials (no.) treated Control (range) (range) Steroid-treated Control value
Intestinal (4) 386 421 18 (12-33) 195 (80-512) 19.4 (16.1-22.7) 16.7 (13.5-19.9) .25
Hepatic (19) 494 485 40 (7-1,250) 28 (9-1,600) 3.9 (2.7-5.0) 2.6 (1.7-3.5) .09
Neurologic (18) 633 590 90 (20-426) 12 (6-180) 166.4 (131.0-201.7) 55.1 (34.7-75.5) <.001
Pulmonary (14) 191 173 30 (13-40) 14 (7-180) 0.0 (0.0-7.8) 0.0 (0.0-8.6) .99
Renal (2) 95 102 26 (11-41) 421 (112-730) 2.6 (0.8-4.6) 0.0 (0.0-1.5) .01
Rheumatic (5) 89 78 8 (5-22) 42 (14-730) 0.0 (0.0-3.4) 0.0 (0.0-4.9) .99
Other (9) 223 238 36 (18-1,926) 20 (3-84) 12.1 (4.5-30.2) 12.9 (4.0-32.4) .95
* Number of infectious complications/(1,OOO patients· 21 d).
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plications were reported. It is conceivable that only
severe infectious complications and/or well-defined
infections (for instance, pneumonia or herpes zos-
ter) were reported, and minor and/or not well de-
fined entities such as urinary tract infection or flu-
like syndromes were omitted. Thus, the quantitative
results of the incidence of infectious complications
derived from the present meta-analysis might indeed
underestimate the true number of infections. Never-
theless, the differences in the incidence of infectious
complications between patients on corticosteroids
and controls are likely to be true, because underre-
porting can be expected in both groups of patients;
overreporting of (expected) infectious complications
in patients on corticosteroids can be excluded, be-
cause similar differences were observed when only
the double-blind studies were analyzed (table 1).
Overall, 13070 and 7070 of the patients with and
without corticosteroid therapy, respectively, had in-
fectious complications. In most trials the patients
were withdrawn from the study when the first infec-
tious complication appeared. Since the point when
the individual infectious complication occurred was
often not indicated, it was not possible to correct
the incidence of infectious complications according
to the true duration of therapy. Therefore, the total
duration of the study for the patients on placebo was
probably slightly longer than for the group of pa-
tients given corticosteroids and thus increased the
likelihood of infectious complications in control sub-
jects. Furthermore, the true incidence of infectious
complications in clinical practice (not under clini-
cal study conditions) might be higher than in the
present analysis because therapy is not usually with-
held when the first infectious complication occurs.
The rate of infectious complications/[l,OOO pa-
tients·21 d] increased from 22.6 in patients given
20-40 mg of prednisone/d to 150.7 in patients given
>40 mg of prednisone/d (table 2). This dose depen-
dency of the incidence of infectious complications
was not paralleled by an increase in the relative risk,
since the incidence of infections rose with increas-
ing dosage in the corresponding control groups as
well (table 2). This indicates that the underlying dis-
ease state, which dictates the dosage regimen of
steroids, largely accounts for the variable and dose-
dependent incidence of infectious complications ob-
served in clinical practice.
Both the relative risk and the rate of infectious
complications/[l,OOO patients·21 d] increased with
increasing cumulative steroid dose up to 1,999 mg
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and declined when a cumulative dose of ~2,OOOmg
of prednisone was given (table 2). The decline of the
relative risk of infectious complications at the highest
cumulative steroid dose may be attributable to in-
vestigations in which a low dose of prednisone was
prescribed for a very long period. Indeed, a mean
daily steroid dose of<10 mg of prednisone for a long
period was not associated with an increased relative
risk of infectious complications (figure 1).
The incidence of infectious complications in pa-
tients treated with parenteral steroid was 484/[1,000
patients·21 d]. This rate has to be interpreted with
caution because the median duration of the trials
with parenteral treatment was <21 days. The reason
for the much higher incidence of infectious compli-
cations in patients given parenteral compared with
patients given oral steroids cannot be attributed to
a low systemic availability of oral steroids [94] but
rather to the high incidence of infectious complica-
tions in the corresponding (parenteral) controls and
to the higher dose of corticosteroids prescribed in
parenteral as opposed to oral form (results not shown).
The underlying disease state was a determinant
of the incidence of infectious complications observed
in control patients. Control patients with neurologic
diseases had the highest incidence of infectious com-
plications among the seven categories of trials (ta-
ble 3). These subjects were the controls of the pa-
tients treated for a relatively short period with the
highest daily dose of prednisone (table 3), a fact sug-
gesting that the entire neurologic patient population
was in a severe disease state that required high ste-
roid doses and made the subjects highly susceptible
to infectious complications. The absence of infec-
tious complications in the control subjects of the
prednisone-treated patients with pulmonary and re-
nal diseases is probably best explained by the short
duration of therapy and/or low dose of prednisone,
a situation indicating a less-severe disease state than
in patients with neurologic diseases (table 3). Alter-
natively, it is conceivable that neurologic diseases pre-
dispose patients to infectious complications more
frequently than the other diseases and/or that the
infectious complications were reported more ac-
curately by the neurologists than by the physicians
conducting the other trials.
While the comparison of the incidence of infec-
tious complications between control subjects with
different underlying diseases is biased by the inves-
tigators who performed the studies, the comparison
of the incidence between patients with and without
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steroid therapy is not. When compared with the mean
relative risk of infectious complications derived from
all the studies analyzed (table 1), the risk in patients
with intestinal, hepatic, renal, or other diseases (ta-
ble 3) was roughly what was expected, while the risk
in patients with neurologic diseases was abnormally
high and in patients with pulmonary or rheumatic
diseases, abnormally low. The threefold increase of
the incidence of infectious complications in steroid-
treated patients with neurologic diseases, compared
with that in control patients with neurologic diseases
(table 3), strongly suggests that this patient popula-
tion exhibits an unusually high sensitivity to the
induction of infectious complications by corticoste-
roids. However, since patients with neurologic dis-
eases were given higher doses of prednisone than
patients with other diseases (table 3), it cannot be
decided whether the higher risk of complications was
attributable to the higher steroid dosage or to a
higher sensitivity to the adverse effects of steroids
as a result of the underlying disease. Similarly, the
absence of an increased risk of infectious complica-
tions in patients with pulmonary or rheumatic dis-
eases might be attributable to the low dosage of pred-
nisone, to the short duration of therapy, or to the
underlying disease state (table 3).
The present analysis revealed no increased risk of
infectious complications in patients given a daily
dose of <10 mg or a cumulative dose of <700 mg
of prednisone. It would be erroneous to conclude
that the prescription of lower doses of prednisone
is absolutely safe for the following reasons. As is true
for all patients participating in controlled clinical
trials, the patients considered in the present meta-
analysis are only partly representative of the patients
treated in clinical practice. For instance, in controlled
clinical trials most patients have a single well-defined
disease, whereas in clinical practice the situation is
often more complicated. In clinical practice one
might have to initiate therapy with prednisone in pa-
tients who are already suffering from an infection
or who are immunocompromised, conditions that
might have precluded the participation in a con-
trolled trial with prednisone. Furthermore, certain
states, such as renal failure, hepatic disease, old age,
or concomitant drug therapy (e.g., ketoconazole or
oral contraceptive steroids), decrease the metabolism
of prednisolone [95-100] and therefore might in-
crease the likelihood of infections even at doses
below the threshold doses for increased risk of in-
fections found in the controlled trials. Conversely,
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patients with an enhanced catabolism of the steroid
because of induced microsomal liver enzymes by
xenobiotics (mainly phenytoin, barbiturates, or ri-
fampin) or because of hyperthyroidism exhibit less
immunosuppressive effect - and as a corollary less
infectious risk - from the same dose of prednisone
than do patients with a normal steroid metabolism
[lOI-103]. Thus, knowledge of the dose of predni-
sone below which no increased risk of infections was
found in controlled trials is only meaningful infor-
mation when it is used in conjunction with knowl-
edge of the pretherapy susceptibility to infection and
the metabolism of the steroid.
This meta-analysis demonstrates within the limits
of the methods employed [16] that glucocorticoids
increase the risk of lethal and nonlethal infectious
complications, a result in accordance with uncon-
trolled observations in clinical practice. In addition,
the analysis of the controlled trials reveals two new
concepts that are of practical relevance: (1) the risk
of prednisone therapy-associated infectious compli-
cations is dose dependent, with no increased risk in
patients given a daily dose of <10 mg or a cumula-
tive dose of <700 mg of prednisone; and (2) the risk
of prednisone therapy-associated infectious compli-
cations is particularly high in patients with neuro-
logic diseases and less pronounced in patients with
intestinal, hepatic, or renal diseases, an indication
that the susceptibility to infection is due not only
to the prednisone therapy but also to the type and
severity of the underlying disease.
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